TD Asset Management
XENE icon

TD Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

TD Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$567K Sell
9,400
-17,674
-65% -$981K ﹤0.01% 1162
2026
Q1 		$1.57M Sell
27,074
-11,074
-29% -$510K ﹤0.01% 1018
2025
Q4 		$1.71M Buy
38,148
+21,918
+135% +$921K ﹤0.01% 1016
2025
Q3 		$652K Buy
+16,230
New +$572K ﹤0.01% 1150
2025
Q1 		– Sell
-20,430
Closed -$801K – 1279
2024
Q4 		$801K Hold
20,430
– – ﹤0.01% 1138
2024
Q3 		$790K Hold
20,430
– – ﹤0.01% 1236
2024
Q2 		$797K Hold
20,430
– – ﹤0.01% 1201
2024
Q1 		$880K Buy
20,430
+4,200
+26% +$193K ﹤0.01% 1193
2023
Q4 		$748K Buy
+16,230
New +$573K ﹤0.01% 1241

Other funds holding XENE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

TD Asset Management's XENE Position: Q2 2026 in Review

TD Asset Management reduced its Xenon Pharmaceuticals (XENE) stake by 65% in Q2 2026, selling an estimated $981K and leaving 9,400 shares worth $567K. The position accounts for ﹤0.01% of the portfolio, ranked #1162.

TD Asset Management first reported a position in XENE in Q4 2023 and has held it in 9 quarters since. The position peaked at $1.71M in Q4 2025. 193 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • TD Asset Management held 9,400 shares of Xenon Pharmaceuticals worth $567K as of Q2 2026.
  • TD Asset Management sold 17,674 Xenon Pharmaceuticals shares in Q2 2026, an estimated $981K.
  • Xenon Pharmaceuticals made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #1162 holding.
  • TD Asset Management first reported a position in Xenon Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
  • TD Asset Management's Xenon Pharmaceuticals position peaked at $1.71M in Q4 2025.
  • 193 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.